These findings have important therapeutic implications as common variants in SIRT3 and UCP2 predicted response to dichloroacetate, pyruvate dehydrogenase kinase inhibitor, in a PAH phase 2 clinical trial [167]. This evidence concerns the gene UCP2 and pulmonary arterial hypertension.